Rebecca Bertolio

Rebecca Bertolio

Auto-generated profile, based on publicly available information

Rebecca Bertolio

International Centre for Genetic Engineering and Biotechnology 1 Trieste, Trieste

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
RBRebecca Bertolio
Rebecca Bertolio
FNFrancesco Napoletano
Francesco Napoletano
MMMiguel Mano
Miguel Mano
SMSebastian Maurer-Stroh
Sebastian Maurer-Stroh
Marco FantuzMarco Fantuz
Marco Fantuz
GSGiannino Del Sal
Giannino Del Sal
Sterol regulatory element binding proteins (SREBPs) are a family of transcription factors that regulate lipid biosynthesis and adipogenesis by controlling the expression of several enzymes required for cholesterol, fatty acid, triacylglycerol and phospholipid synthesis. In vertebrates, SREBP activation is mainly controlled by a complex and well-characterized feedback mechanism mediated by cholesterol, a crucial bio-product of the SREBP-activated mevalonate pathway. In this work, we identified acto-myosin contractility and mechanical forces imposed by the extracellular matrix (ECM) as SREBP1 regulators. SREBP1 control by mechanical cues depends on geranylgeranyl pyrophosphate, another key bio-product of the mevalonate pathway, and impacts on stem cell fate in mouse and on fat storage in Drosophila. Mechanistically, we show that activation of AMP-activated protein kinase (AMPK) by ECM stiffening and geranylgeranylated RhoA-dependent acto-myosin contraction inhibits SREBP1 activation. Our results unveil an unpredicted and evolutionary conserved role of SREBP1 in rewiring cell metabolism in response to mechanical cues.

19 January 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
GSGiovanni Sorrentino
Giovanni Sorrentino
NRNaomi Ruggeri
Naomi Ruggeri
AZAlessandro Zannini
Alessandro Zannini
EIEleonora Ingallina
Eleonora Ingallina
RBRebecca Bertolio
Rebecca Bertolio
GSGiannino Del Sal
Giannino Del Sal
The Hippo pathway is an oncosuppressor signalling cascade that plays a major role in the control of cell growth, tissue homoeostasis and organ size. Dysregulation of the Hippo pathway leads to aberrant activation of the transcription co-activator YAP (Yes-associated protein) that contributes to tumorigenesis in several tissues. Here we identify glucocorticoids (GCs) as hormonal activators of YAP. Stimulation of glucocorticoid receptor (GR) leads to increase of YAP protein levels, nuclear accumulation and transcriptional activity in vitro and in vivo. Mechanistically, we find that GCs increase expression and deposition of fibronectin leading to the focal adhesion-Src pathway stimulation, cytoskeleton-dependent YAP activation and expansion of chemoresistant cancer stem cells. GR activation correlates with YAP activity in human breast cancer and predicts bad prognosis in the basal-like subtype. Our results unveil a novel mechanism of YAP activation in cancer and open the possibility to target GR to prevent cancer stem cells self-renewal and chemoresistance.

18 December 2017 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
EIEleonora Ingallina
Eleonora Ingallina
GSGiovanni Sorrentino
Giovanni Sorrentino
RBRebecca Bertolio
Rebecca Bertolio
KLKamil Lisek
Kamil Lisek
AZAlessandro Zannini
Alessandro Zannini
GSGiannino Del Sal
Giannino Del Sal
Tumour-associated p53 missense mutants act as driver oncogenes affecting cancer progression, metastatic potential and drug resistance (gain-of-function)1. Mutant p53 protein stabilization is a prerequisite for gain-of-function manifestation; however, it does not represent an intrinsic property of p53 mutants, but rather requires secondary events2. Moreover, mutant p53 protein levels are often heterogeneous even within the same tumour, raising questions on the mechanisms that control local mutant p53 accumulation in some tumour cells but not in their neighbours2,3. By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment. Our results provide evidence for an unpredicted layer of mutant p53 regulation that relies on metabolic and mechanical cues.

25 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CTCamilla Tombari
Camilla Tombari
AZAlessandro Zannini
Alessandro Zannini
RBRebecca Bertolio
Rebecca Bertolio
SPSilvia Pedretti
Silvia Pedretti
MAMatteo Audano
Matteo Audano
GSGiannino Del Sal
Giannino Del Sal
Reprogramming of amino acid metabolism, sustained by oncogenic signaling, is crucial for cancer cell survival under nutrient limitation. Here we discovered that missense mutant p53 oncoproteins stimulate de novo serine/glycine synthesis and essential amino acids intake, promoting breast cancer growth. Mechanistically, mutant p53, unlike the wild-type counterpart, induces the expression of serine-synthesis-pathway enzymes and L-type amino acid transporter 1 (LAT1)/CD98 heavy chain heterodimer. This effect is exacerbated by amino acid shortage, representing a mutant p53-dependent metabolic adaptive response. When cells suffer amino acids scarcity, mutant p53 protein is stabilized and induces metabolic alterations and an amino acid transcriptional program that sustain cancer cell proliferation. In patient-derived tumor organoids, pharmacological targeting of either serine-synthesis-pathway and LAT1-mediated transport synergizes with amino acid shortage in blunting mutant p53-dependent growth. These findings reveal vulnerabilities potentially exploitable for tackling breast tumors bearing missense TP53 mutations.

6 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CTCamilla Tombari
Camilla Tombari
AZAlessandro Zannini
Alessandro Zannini
RBRebecca Bertolio
Rebecca Bertolio
SPSilvia Pedretti
Silvia Pedretti
MAMatteo Audano
Matteo Audano
GSGiannino Del Sal
Giannino Del Sal

28 October 2026 in Cancer Discovery
Verified
Journal Article
Open access
RBRebecca Bertolio
Rebecca Bertolio
ARAlessandra Rustighi
Alessandra Rustighi
ARAnna Renzi
Anna Renzi
ECElena Campaner
Elena Campaner
VCValeria Cancila
Valeria Cancila
GSGiannino Del Sal
Giannino Del Sal
Breast cancers with a stiff extracellular matrix (ECM) frequently evade immune surveillance through mechanisms that remain incompletely understood. Here, we identify a mechanosensitive immune-evasion pathway governed by the phosphorylation-dependent prolyl isomerase Pin1. We show that ECM rigidity stabilizes Pin1 and promotes its nuclear accumulation in cancer cells, where it preserves heterochromatin organization and nuclear envelope integrity by sustaining HP1α-Lamin interactions, thereby suppressing transposable element (TE) activity. Pin1 loss induces early heterochromatin relaxation and LINE1 reactivation, activating the cGAS/STING/type I interferon pathway. Pin1 depletion further promotes TE-derived neoantigen generation and broadly remodels the tumor immune microenvironment, eliciting innate and adaptive immune responses that enhance tumor clearance. Genetic Pin1 depletion, or pharmacological inhibition with clinically available drugs, sensitizes fibrotic, immune-cold tumors to immune checkpoint blockade. These findings uncover a mechano-genomic mechanism of immune evasion in breast cancer and establish Pin1 as a therapeutic target to restore tumor immunogenicity and improve immunotherapy efficacy.